UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

A new study by UCSF researchers reveals that long-acting injectable treatments offer a promising alternative for HIV patients who find it challenging to adhere to daily pill regimens. This ...

Patients who struggle to take daily HIV pills can benefit from long-acting ... the UCSF HIV/AIDS clinic at Zuckerberg San Francisco General Hospital. They studied data from 370 patients ...